Frankfurt - Delayed Quote EUR

Daiichi Sankyo Company, Limited (D4S.F)

22.87
+0.28
+(1.24%)
As of 8:06:16 AM GMT+2. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for D4S.F

Recent News: D4S.F

View More
MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug

MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug
Zacks yesterday
Daiichi Sankyo and MSD announce first subject dosing in oesophageal cancer trial

Daiichi Sankyo and MSD announce first subject dosing in oesophageal cancer trial
Clinical Trials Arena 2 days ago
IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Business Wire 2 days ago
Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices
The Wall Street Journal 10 days ago
AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial

AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial
Clinical Trials Arena 14 days ago
ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial

ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial
Business Wire 15 days ago
TAK or DSNKY: Which Is the Better Value Stock Right Now?

TAK or DSNKY: Which Is the Better Value Stock Right Now?
Zacks 19 days ago
Daiichi and AstraZeneca’s Enhertu shows PFS benefits in breast cancer trial

Daiichi and AstraZeneca’s Enhertu shows PFS benefits in breast cancer trial
Clinical Trials Arena 30 days ago
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients
Benzinga 30 days ago
ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer

ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer
Business Wire last month
TAK vs. DSNKY: Which Stock Is the Better Value Option?

TAK vs. DSNKY: Which Stock Is the Better Value Option?
Zacks last month
View More

Related Tickers

SNW2.F Sanofi
46.60
0.00%
 
4578.T Otsuka Holdings Co., Ltd.
6,634.00
+0.05%
 
4503.T Astellas Pharma Inc.
1,390.50
+0.76%
 
ROG.SW Roche Holding AG
259.20
-1.29%
 
SNY Sanofi
52.90
+0.02%
 
BAYN.DE Bayer Aktiengesellschaft
24.10
+1.60%
 
GSK GSK plc
38.54
+0.36%
 
AZN AstraZeneca PLC
69.68
-0.34%
 
ABBV AbbVie Inc.
181.80
-1.65%
 
JNJ Johnson & Johnson
153.18
-0.31%